The standard treatment of patients with advanced epithelial ovarian cancer consists in surgical debulking followed by platinum-containing chemotherapy. Despite the high initial objective response rate of ovarian carcinomas to the various platinum-based therapy regimens, the majority of patients ultimately develop disease progression and die from complications of their cancer within the first 5 years after diagnosis. Because of poor long-term survival, more aggressive therapeutic strategies, including intraperitoneal and high-dose chemotherapy with autologous bone marrow rescue, are currently under discussion for introduction into frontline chemotherapy.
However, criteria to be considered for the selection of patients for these treatment regimens remain to be defined. A more accurate assessment of prognosis is certainly of pivotal importance when identifying patients who may benefit most from such therapy protocols. In addition to the established clinicopathological characteristics of the disease, new determinants of favourable or aggressive tumour behaviour are needed to improve the estimation of individual prognosis. Therefore, investigations focusing on the evaluation of new prognostic factors are of significant interest.
In this regard, adhesion molecule CD44 has attracted attention when certain of its variant isoforms conferred metastatic potential on primarily non-metastasizing rat pancreatic tumour cell lines in an animal tumour model (Gunthert et al, 1991; Seiter et al, 1993 ). CD44 was first described by Jalkanen et al (1987) as a lymphocytehoming receptor, regulating the entry of circulating lymphocytes into the lymphatic tissue by attachment to endothelial venules. However, this adhesion molecule is not only present on lymphocytes but is ubiquitously expressed on cells of mesodermal and haemopoietic origin (Terpe et al, 1994) . CD44 acts as a principal receptor for hyaluronate and is involved in cell-cell or cell-extracellular matrix interactions (Miyake et al, 1990) .
The CD44 gene consists of 20 exons, ten of which are constitutively expressed in the standard form of CD44 (CD44s). By a mechanism referred to as 'alternative messenger RNA splicing', the remaining ten exons can be assembled in a variable number in conjunction with CD44s transcripts, resulting in the synthesis of a variety of so-called CD44 variant isoforms (CD44v) that differ from CD44s by additional amino acids inserted into the extracellular domain of the protein. In a broad range of carcinomas, including those of the stomach, colon, breast and ovary, overexpression of specific CD44 variant isoforms was shown to be associated with poor prognosis (Heider et al, 1993; Mayer et al, 1993; Mulder et al, 1994; Guinthert et al, 1995; Kaufmann et al, 1995; Uhl-Steidl et al, 1995) . Although the functions of CD44v in tumour biology are not fully understood, it has been speculated that certain alternatively spliced formns of CD44 play a causal role in tumour progression and particularly in lymphatic metastatic spread (Salles et al, 1993; Seiter et al, 1993) .
CD44 isoforms not only exist as membrane-integrated molecules, but are also shed from the cellular surface and thus occur as soluble CD44 molecules in body fluids. Monoclonal antibodies, which have recently been raised against soluble CD44s and its variant isoform-carrying domains encoded by exon v5 and v6, enabled us to determine the pretreatment serum and ascitic levels of these molecules in women suffering from ovarian cancer. The major aim of the present investigation was the evaluation of the prognostic value of CD44 variant isoforms in ovarian cancer. In addition, we were interested in whether one or the other of these 5 ml of serum to be subjected to scientific determination of circulating CD44s and its variant isoforms.
Serum assays
Serum samples were taken before surgery and were stored at -20°C until assayed. Serum concentrations of soluble CD44s, CD44v5, and CD44v6 were measured using the commercially available enzyme-linked immunosorbent assays: sCD44std ELISA; sCD44var (v5) ELISA; and sCD44var (v6) ELISA. The kits were a generous gift from Bender MedSystems (Bender, Vienna, Austria). All determinations of soluble CD44 isoforms were performed in triplicate according to the manufacturer's instructions. The intra-and intra-assay coefficients of variation (CV) were 5.3% and 3.2%, respectively, for the sCD44std assay, 6.2% and 4.8%, respectively, for the sCD44var (v5) assay and 5.8% and 5.0%, respectively, for the sCD44var (v6) assay. The limits of detection determined by the manufacturer were 0.07 ng ml-', 0.22 ng ml-' and 0.09 ng ml-1 for the soluble CD44s, CD44v5 and CD44v6 respectively. Preoperative CA 125 serum levels were determined with a sandwich solid-phase radioimmunoassay (Centocor, Malvem, PA, USA) according to the manufacturer's recommendations. The inter-and intra-assay CV were 5.3% and 4.2% respectively. Neopterin serum concentrations were measured using a radioimmunoassay based on the double-antibody technique (Henning, Berlin, Germany). Incubations were carried out under protection from light according to the instructions of the manufacturer (interand intra-assay CV 10.5% and 7.1% respectively).
The serum content of immunosuppressive acidic protein (IAP) was measured with a single radial immunodiffusion test (Sanko Junyaku, Tokyo, Japan). Five microlitres of serum were applied to each well of the gel plate containing anti-IAP rabbit serum. After incubation at 37°C for 60 h in a humid atmosphere the diameter of the precipitation rings was measured. The values were compared with those obtained from calibration standards of purified IAP (inter-/intra-assay CV 5.7% and 3.7% respectively).
s-IL-2R was determined with an immunoenzymometric assay kit purchased from Immunotech International (SA, Marseille, France); inter-and intra-assay CV were 6.5% and 4.0% respectively. Serum 90K was determined with a newly developed immunoradiometric assay (IRMA), as described previously (Zeimet et al, 1996) . The inter-and intra-assay CV of this assay were 7.2% and 4.4% respectively.
Haemoglobin concentration and total white blood cell count were determined by the Clinical Chemistry Facility at Innsbruck University Hospital; the normal range as defined by the 95% confidence limit was 7.27-9.75 mmol 1-1 and 4-10 x 109 1-' respectively.
Statistics
Statistical analysis was performed using the BMDP software package. Data Table 2 and shown in Figure 1, When soluble CD44 isoforms were compared with other serum parameters, variant isoform v5 was negatively related to immunostimulatory protein 90K (rs = -0.2152; P < 0.05), soluble interleukin 2 receptor (s-IL-2R) (rs = -0.2536; P < 0.05) and neopterin (rs = -0.346; P < 0.01). In contrast, serum levels of CD44 v6 were negatively associated with serum CA-125 (rs = -0.2585; P < 0.01) and IAP (rs = -0.2553; P < 0.01).
Fifty-four patients (56%) had significant amounts of ascites. Concentrations of soluble CD44s, isoforms vS and v6 in the ascitic fluid are shown in Table 2 . Whereas vS and v6 content was significantly lower in ascitic fluid than in serum (P < 0.01 and P < 0.001 respectively), CD44s did not differ in either compartment.
Analysis of overall survival revealed no prognostic value, either for serum CD44s or for the v6 isoform. However, patients with pretreatment concentrations of circulating variant isoform vS higher than the Q3 value determined in the present collective (35 ng ml-') showed a significantly better survival than patients presenting with lower vS serum levels (P < 0.01) (Figure 2) . During a median follow-up period of 29 months only 4 out of 24 patients (17%) with vS serum levels above the cut-off value of 35 ng ml-' died from the disease, whereas in the cohort of patients with lower circulating vS concentrations 33 out of 72 patients (46%) died. Table 3 compares characteristics of patients with circulating v5 isoform levels higher than 35 ng ml-' with those of patients with lower vS serum content. This comparison revealed that high-grade tumours are frequently associated with vS serum levels below the cut-off value of 35 ng ml-' (P < 0.05) and that patients with low circulating CD44vS levels showed significantly higher serum concentrations of CA-125, neopterin (P < 0.03) and immunostimulatory protein 90K (P < 0.05).
Furthermore, in multivariate Cox regression analysis (Table 4) , serum isoform vS retained independent prognostic significance (RR 0.58; P < 0.05) together with FIGO stage (RR 4.5; P < 0.0001), residual disease and histopathological grading (RR 1.89 and 2.4 respectively; P < 0.001). None of the various CD44 isoforms, when investigated in ascitic fluid, was found to be of prognostic relevance. (Lein et al, 1996) . In agreement with the data of Sliutz et al (1995) , none of the herein investigated soluble isoforms of the CD44 family can be expected to represent a useful tumour marker in ovarian cancer.
The association of high circulating levels of CD44v5 isoforms with favourable prognosis represents a very interesting outcome of the present study. Even although, to our knowledge, the prognostic significance of soluble CD44 isoforms has not yet been evaluated, this finding was unexpected compared with the early experimental data from studies obtained in a rat tumour model, in which cellular expression of alternatively spliced CD44 variant isoforms conferred metastatic potential or primarily non-metastasizing pancreatic tumour cells (Gunthert et al, 1991; Arch et al, 1992) . Furthermore, a number of clinical studies have provided evidence that up-regulation of certain CD44 isoforms in tumour cells is related to adverse clinical outcome (Mayer et al, 1993; Stauder et al, 1995) . However, the results concerning the prognostic value of the immunohistochemically assessed cellular expression of CD44 variant isoforms have been controversial in breast, colorectal and ovarian cancer (Mulder et al, 1994; Cannistra et al, 1995; Friedrichs et al, 1995; Kaufmann et al, 1995; Koretz et al, 1995; Uhl-Steidl et al, 1995) .
In 44 patients with advanced ovarian cancer, tissue expression of CD44 splice variants, detected immunohistochemically by polyclonal antibody-recognizing variant exons v3-vlO of human CD44, was found to be associated with short disease-free and overall survival in univariate analysis (Uhl-Steidl et al, 1995) . In an additional study, however, tissue expression of CD44s and its various alternatively spliced isoforms, as determined by monoclonal antibodies and reverse transcription polymerase chain reaction, failed to exhibit an association with survival in 31 ovarian cancer patients (Cannistra et al, 1995) . These authors commonly detected CD44s and isoform v9, but not the isoforms vS or v6, in ovarian cancer tissue (Cannistra et al, 1995) . Accordingly, Sliutz et al (1995) demonstrated only traces of CD44v5 and v6 proteins in 2 out of 22 immunohistochemically investigated ovarian carcinoma samples. This is in agreement with our own observations based on immunohistochemical studies using the monoclonal antibodies VFF-8 and VFF-7, which recognize CD44 variant isoforms vS and v6 respectively (data not shown).
Modest immnunohistochemical detection alone does not necessarily exclude ovarian cancer cells as a source of soluble CD44 variant isoforms, as Yu and Toole (1996) recently demonstrated mRNA for CD44 isoforms that contained stop codons positioned so that translated proteins are truncated before the transmembrane domain and thus secreted directly as soluble molecules without transient membrane integration. However, the unconvincing immunohistochemical results in the detection of isoforms vS and v6 in ovarian cancer tissue together with the findings of the current investigation, showing that CD44v5 serum content is lower in ovarian cancer patients than in healthy female control subjects and that splice variants v5 and v6 are present at significantly lower levels in ascitic fluid than in serum, indicate that ovarian cancer cells are not a relevant source of circulating CD44 isoforms v5 and v6.
As the present study reveals that soluble CD44v5 was inversely correlated with circulating immunostimulatory protein 90K, s-IL-2-R and serum neopterin, all of which belong to a group of molecules regarded as indicators of cellular immune-system activation (Marth et al, 1993; Zeimet et al, 1996) , it cannot be ruled out that changes in systemic levels of soluble CD44v5 are due to tumourinduced alterations in the host's immune defence. This hypothesis is conceivable as expression of CD44 isoforms, including that of v5, in peripheral blood leucocytes was recently found to be inversely correlated to tumour progression in patients with haematological malignancies (Khaldoyanidi et al, 1996) . The assumption of immunologically induced changes in systemic CD44v5 levels is further supported by the postulated pivotal role of cytokines in shedding soluble CD44 isoforms (Ristamaki et al, 1994) .
To elucidate the involvement of the immune system in the regulation of circulating CD44 variant isoforms, we are currently investigating the constitutive and cytokine-modulated secretion of CD44 isoforms by immunocompetent cells under in vitro conditions. In addition, a prospective evaluation in a larger cohort is required to substantiate further the association of high circulating CD44v5 levels with favourable clinical course in ovarian cancer patients.
